There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Activated effector T (TE) cells augment anabolic pathways of metabolism, such as aerobic
glycolysis, while memory T (TM) cells engage catabolic pathways, like fatty acid oxidation
(FAO). However, signals that drive these differences remain unclear. Mitochondria
are metabolic organelles that actively transform their ultrastructure. Therefore,
we questioned whether mitochondrial dynamics controls T cell metabolism. We show that
TE cells have punctate mitochondria, while TM cells maintain fused networks. The fusion
protein Opa1 is required for TM, but not TE cells after infection, and enforcing fusion
in TE cells imposes TM cell characteristics and enhances antitumor function. Our data
suggest that, by altering cristae morphology, fusion in TM cells configures electron
transport chain (ETC) complex associations favoring oxidative phosphorylation (OXPHOS)
and FAO, while fission in TE cells leads to cristae expansion, reducing ETC efficiency
and promoting aerobic glycolysis. Thus, mitochondrial remodeling is a signaling mechanism
that instructs T cell metabolic programming.
In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect." Aerobic glycolysis is an inefficient way to generate adenosine 5'-triphosphate (ATP), however, and the advantage it confers to cancer cells has been unclear. Here we propose that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell. Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-associated mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP production. A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer.
Failure of T cells to protect against cancer is thought to result from lack of antigen recognition, chronic activation, and/or suppression by other cells. Using a mouse sarcoma model, we show that glucose consumption by tumors metabolically restricts T cells, leading to their dampened mTOR activity, glycolytic capacity, and IFN-γ production, thereby allowing tumor progression. We show that enhancing glycolysis in an antigenic "regressor" tumor is sufficient to override the protective ability of T cells to control tumor growth. We also show that checkpoint blockade antibodies against CTLA-4, PD-1, and PD-L1, which are used clinically, restore glucose in tumor microenvironment, permitting T cell glycolysis and IFN-γ production. Furthermore, we found that blocking PD-L1 directly on tumors dampens glycolysis by inhibiting mTOR activity and decreasing expression of glycolysis enzymes, reflecting a role for PD-L1 in tumor glucose utilization. Our results establish that tumor-imposed metabolic restrictions can mediate T cell hyporesponsiveness during cancer.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.